BIIB - Biogen Inc Stock Price, Fair Value and News

211.19USD-16.25 (-7.14%)Market Closed

Market Summary

USD211.19-16.25

Market Closed

-7.14%

BIIB Stock Price

View Fullscreen

BIIB RSI Chart

BIIB Valuation

Market Cap

30.7B

Price/Earnings (Trailing)

26.36

Price/Sales (Trailing)

3.18

EV/EBITDA

17.07

Price/Free Cashflow

22.14

BIIB Price/Sales (Trailing)

BIIB Profitability

Operating Margin

94.35%

EBT Margin

13.69%

Return on Equity

7.67%

Return on Assets

4.39%

Free Cashflow Yield

4.52%

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

9.7B

Rev. Growth (Yr)

-7%

Rev. Growth (Qtr)

-4.01%

BIIB Earnings

Earnings (TTM)

1.2B

Earnings Growth (Yr)

1.42%

Earnings Growth (Qtr)

57.55%

Breaking Down BIIB Revenue

Last 7 days

1.0%

Last 30 days

1.9%

Last 90 days

8.9%

Trailing 12 Months

-14.2%

How does BIIB drawdown profile look like?

BIIB Financial Health

Current Ratio

2.1

Debt/Equity

0.41

Debt/Cashflow

0.26

BIIB Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

8.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.7B	0	0	0
2023	10.1B	10.0B	10.0B	9.8B
2022	10.8B	10.6B	10.4B	10.2B
2021	12.6B	11.7B	11.1B	11.0B
2020	14.4B	14.5B	14.3B	13.4B
2019	13.8B	14.1B	14.2B	14.4B
2018	12.6B	12.9B	13.2B	13.5B
2017	11.5B	11.7B	11.8B	12.3B
2016	10.9B	11.2B	11.4B	11.4B
2015	10.1B	10.3B	10.6B	10.8B
2014	7.6B	8.3B	9.0B	9.7B
2013	5.6B	5.9B	6.4B	6.9B
2012	5.1B	5.3B	5.4B	5.5B
2011	4.8B	4.8B	4.9B	5.0B
2010	4.4B	4.6B	4.6B	4.7B
2009	4.2B	4.3B	4.3B	4.4B
2008	0	3.5B	3.8B	4.1B
2007	0	0	0	3.2B

Get all data in R, Python etc through our Historical Stock Data APIs

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Christopher A. Viehbacher
WEBSITE	biogen.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	8725

Biogen Inc Frequently Asked Questions

What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biogen Inc (BIIB)?

As of Thu Jul 25 2024, market cap of Biogen Inc is 33.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers.

Is Biogen Inc a good stock to buy?

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, BIIB's PE ratio (Price to Earnings) is 28.39 and Price to Sales (PS) ratio is 3.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biogen Inc's stock?

In the past 10 years, Biogen Inc has provided -0.03 (multiply by 100 for percentage) rate of return.